Syphilis Testing Market: The Technology Shift From Immunoassays to Molecular Diagnostics
Syphilis was nearly written off as a solved problem in high-income countries after penicillin became widely available in the mid-20th century. That assumption no longer holds. Case counts have rebounded sharply over the past decade, and diagnostics companies, public health agencies, and hospital labs are racing to keep pace. Here's what the data shows — and what it signals for the diagnostics industry over the next several years. Market Snapshot: The Numbers Behind the Resurgence The global syphilis testing market was valued at USD 1.5 billion in 2025, with an estimated size of USD 1.6 billion in 2026. By 2033, the market is forecast to reach USD 2.3 billion, growing at a CAGR of 5.2% from 2026 to 2033. Compared to high-flying technology markets, a 5.2% CAGR looks modest on paper. But context matters here: this is a mature diagnostic category being reignited by an epidemiological trend, not a new technology creating its own demand. Growth driven by disease resurgence tends to ...